Skip to content
Pass Duke Elder
Textbook / Chapter 13 / Ocular pharmacology and therapeutics

Anti-VEGF and other intravitreal treatment

Injecting drugs into the vitreous has changed the outlook for wet macular degeneration, diabetic macular oedema and retinal vein occlusion, and it is now one of the commonest procedures in the NHS. This lesson explains what VEGF does, how the anti-VEGF drugs differ as molecules and what each binds, how the injection is given, and what can go wrong. When to treat each disease, and the trial evidence, are covered in the medical retina chapter.

9 minute read3 linked questions

What VEGF does

Vascular endothelial growth factor (VEGF) is a signalling protein that tells blood vessels to grow and to become leaky. Retinal cells make more of it when they are short of oxygen. In a growing embryo, or a healing wound, that response is useful. In the adult retina it is destructive. A retina starved of blood by diabetes or a vein occlusion releases VEGF, and the result is leaking capillaries, which cause macular oedema, and fragile new vessels, which bleed. In wet age-related macular degeneration, VEGF drives new vessels to grow from the choroid under the macula.

VEGF is a family. VEGF-A is the main driver of new vessel growth and leak in the eye, and exists in several forms (isoforms) of different lengths. VEGF-B and placental growth factor (PlGF) are relatives. The signals are received by receptors on endothelial cells: VEGFR1, which binds VEGF-A, VEGF-B and PlGF, and VEGFR2, which binds VEGF-A and produces most of the growth and permeability effects.

A second pathway works alongside VEGF. Angiopoietin-2 (Ang-2) acts on a receptor called Tie2 and makes vessels unstable and more responsive to VEGF. Hypoxia and high glucose increase it. The newest drug blocks this pathway too.

An anti-VEGF drug is a protein that binds VEGF in the vitreous and retina before it can reach its receptor. Leak dries up within days to weeks and new vessels regress. The drug is slowly cleared from the eye, the disease is still active, and so the injection has to be repeated, often for years.

The drugs and what each binds

The drugs are all engineered proteins but they are built differently, and examiners ask about the differences. An antibody has two antigen-binding arms (each called a Fab) joined to a stem (the Fc portion).

DrugWhat it isSizeBinds
BevacizumabFull-length humanised monoclonal antibody149 kDaAll isoforms of VEGF-A
RanibizumabHumanised antibody fragment (Fab)48 kDaAll isoforms of VEGF-A
AfliberceptFusion protein: binding domains of VEGFR1 and VEGFR2 joined to the Fc of IgG1115 kDaVEGF-A, VEGF-B and PlGF
BrolucizumabSingle-chain antibody fragment26 kDaVEGF-A
FaricimabBispecific antibodyAbout 150 kDaVEGF-A and angiopoietin-2
Anti-VEGF agents compared

Pegaptanib was the first anti-VEGF drug approved for wet macular degeneration. It blocked only one isoform, VEGF-A 165, and was replaced when drugs that block all isoforms gave much better vision.

Bevacizumab was developed as an intravenous cancer drug for bowel cancer. Ophthalmologists began injecting small doses into the eye, outside its licence, in 2005, and it has been used that way around the world because it is cheap. A formulation made for the eye, bevacizumab gamma, is now licensed for wet macular degeneration. The BNF states that the intravenous product and bevacizumab gamma are not interchangeable.

Ranibizumab is an antibody fragment (a Fab) developed specifically for the eye. With no Fc stem it is about a third of the size of bevacizumab, which was intended to help it diffuse from the vitreous into the retina.

Aflibercept is not an antibody. It is a decoy receptor: the VEGF-binding parts of the two natural receptors, fused to an antibody stem. Because it uses the receptors' own binding sites it holds VEGF very tightly and also traps VEGF-B and PlGF. The UK product information names VEGF-A and PlGF as its targets; binding of VEGF-B is described in the published literature. It was the first agent tested with a longer interval between maintenance injections.

Brolucizumab is the smallest. Its small size allows many more molecules to be packed into the same injected volume. Its drawback is a safety signal described below.

Faricimab is the first bispecific antibody for the eye: one arm binds VEGF-A and the other binds Ang-2. Blocking both pathways is intended to stabilise vessels for longer, so that injections can be spaced further apart.

What they are used for

The licensed indications overlap. In the BNF, ranibizumab, aflibercept and faricimab are all listed for neovascular (wet) age-related macular degeneration, diabetic macular oedema and macular oedema secondary to retinal vein occlusion. Ranibizumab and aflibercept are also used for choroidal new vessels from pathological myopia, and ranibizumab for proliferative diabetic retinopathy. Brolucizumab is listed for wet macular degeneration and diabetic macular oedema. Anti-VEGF injection is also one treatment for retinopathy of prematurity, covered in the paediatric chapter.

Treatment usually starts with a loading phase of monthly injections. After that, most units use a treat-and-extend approach: if the macula is dry on optical coherence tomography, the gap to the next injection is lengthened step by step, and it is shortened again if fluid returns. The aim is the fewest injections that keep the retina dry.

How an intravitreal injection is given

The injection is an outpatient procedure that takes a few minutes, and in the UK it is often given by trained nurses and other non-medical practitioners. The steps are designed around one aim, which is keeping bacteria out of the eye.

  1. Topical anaesthetic drops are instilled.
  2. Povidone-iodine 5% is applied to the conjunctival sac and left in contact with the surface. This is the single most important step in preventing infection.
  3. A sterile lid speculum holds the lids and lashes away from the injection site.
  4. The site is measured from the limbus: 3.5 to 4 mm behind it in an eye with its natural lens (phakic), and 3 to 3.5 mm in an eye with a lens implant (pseudophakic).
  5. A fine 30-gauge needle is passed through the sclera towards the centre of the globe and a small volume, typically 0.05 mL, is injected.
  6. Afterwards the practitioner confirms that the eye can still see, which shows the optic nerve head is perfused, and checks the pressure if there is concern.

The distance from the limbus is chosen so that the needle enters through the pars plana, the flat posterior part of the ciliary body. In front of it lie the lens and the vascular ciliary processes. Behind it the retina begins at the ora serrata. The pars plana is the one zone where a needle can enter the vitreous without touching either.

3D atlasThe needle enters through the pars plana, behind the lens and in front of the retina.

Antibiotic drops before or after the injection are not routinely used. Studies have not shown that they reduce endophthalmitis, and repeated courses breed resistant conjunctival bacteria.

Risks of the injection and of the drugs

The risks come from three sources: the needle, the volume and the drug.

SourceComplicationComment
NeedleInfectious endophthalmitisThe most feared; roughly 1 in 3,000 injections in large series
NeedleRetinal tear or detachment, lens injury and cataract, vitreous haemorrhageUncommon; depend on site and direction of the needle
NeedleSubconjunctival haemorrhageCommon and harmless
VolumeRise in intraocular pressureUsually brief; can close the central retinal artery if severe
DrugTear of the retinal pigment epitheliumListed in the BNF as common with ranibizumab, aflibercept, brolucizumab and faricimab
DrugIntraocular inflammationA particular concern with brolucizumab
DrugArterial thromboembolismA theoretical systemic risk; frequency not known
Complications of intravitreal anti-VEGF

Endophthalmitis is rare per injection, but a patient may have dozens of injections, so the cumulative risk is real. It presents within days with increasing pain, redness and falling vision. Patients are told to return immediately if this happens, and it is managed as described in the vitreoretinal chapter, with a vitreous sample and intravitreal antibiotics.

Brolucizumab carries an MHRA warning. Intraocular inflammation, including retinal vasculitis and retinal vascular occlusion, has been reported, mostly early in treatment and more often in patients who develop antibodies against the drug. Maintenance doses must not be given less than 8 weeks apart, and the drug is stopped if these events occur.

The BNF contraindicates anti-VEGF injection in the presence of ocular or periocular infection or active severe intraocular inflammation, and advises stopping treatment if a rhegmatogenous retinal detachment or a stage 3 or 4 macular hole develops. Small amounts of drug reach the circulation, and VEGF is essential for placental and fetal blood vessels, so women who could become pregnant are advised to use effective contraception during treatment and for at least 3 months after the last dose of ranibizumab, aflibercept or faricimab.

Other drugs given into the vitreous

The same route is used for other drug groups, each met elsewhere in this book.

  • Corticosteroids: the dexamethasone implant, the fluocinolone implant and triamcinolone, for macular oedema and non-infectious uveitis. They treat the inflammatory part of oedema that anti-VEGF drugs do not, at the cost of cataract and raised pressure.
  • Antimicrobials: vancomycin with ceftazidime for bacterial endophthalmitis, amphotericin B or voriconazole for fungal infection, and ganciclovir for cytomegalovirus retinitis.
  • Complement inhibitors: pegcetacoplan and avacincaptad pegol, developed for geographic atrophy in dry macular degeneration and discussed in the lesson on that disease. They are given in a larger volume (0.1 mL) than anti-VEGF drugs.

Summary

  • VEGF-A is released by hypoxic retina and causes vascular leak and new vessel growth.
  • Anti-VEGF drugs bind VEGF in the eye and must be repeated because they are cleared while the disease continues.
  • Bevacizumab is a full antibody, ranibizumab is a Fab fragment, and brolucizumab is a single-chain fragment; all bind VEGF-A.
  • Aflibercept is a decoy receptor fusion protein that binds VEGF-A, VEGF-B and placental growth factor.
  • Faricimab is a bispecific antibody against VEGF-A and angiopoietin-2.
  • The main indications are wet macular degeneration, diabetic macular oedema and macular oedema after retinal vein occlusion.
  • The injection goes through the pars plana, 3.5 to 4 mm behind the limbus in a phakic eye and 3 to 3.5 mm in a pseudophakic eye.
  • Povidone-iodine 5% is the key step in preventing endophthalmitis; routine antibiotic drops are not used.
  • Endophthalmitis follows roughly 1 in 3,000 injections and presents with pain and falling vision within days.
  • Brolucizumab can cause intraocular inflammation with retinal vasculitis and vascular occlusion.

Check yourself

Quick recall on this lesson. These are easier than the question bank.

1. Which anti-VEGF agent is a fusion protein that acts as a decoy receptor?
2. Besides VEGF-A, which molecule does faricimab bind?
3. In a phakic eye, how far behind the limbus is an intravitreal injection given?
4. Which antiseptic is applied to the conjunctiva before an intravitreal injection?
Practise 3 questions on this lesson

Written for revision. It is not a source of clinical advice, and guidance changes.